Suggested remit - To appraise the clinical and cost effectiveness of siponimod within its marketing authorisation for treating secondary progressive multiple sclerosis in adults
 
Status In progress
Process STA 2018
ID number 1304

Provisional Schedule

Committee meeting: 1 12 March 2020
Expected publication 03 June 2020

Project Team

Project lead Jo Ekeledo

Email enquiries

Evidence Review Group / Assessment Group Warwick Evidence, Warwick Medical School, University of Warwick

Consultees

Companies sponsors Novartis (siponimod)
Others Department of Health and Social Care
  NHS England
  Welsh Government
Patient carer groups Multiple Sclerosis Society
  Multiple Sclerosis Trust
Professional groups Association of British Neurologists
  Royal College of Physicians
  UK Clinical Pharmacy Association
  UK Multiple Sclerosis Specialist Nurse Association

Commentators

Comparator companies Novartis (interferon beta 1b)
  Bayer (interferon beta 1b) - (confidentiality agreement not signed, not participating)
  Biogen (dimethyl fumarate, interferon beta 1a)
  Merck (interferon beta 1a) (confidentiality agreement not signed, not participating)
  Mylan (glatiramer acetate) (confidentiality agreement not signed, not participating)
  Roche (ocrelizumab) (confidentiality agreement not signed, not participating)
  Sanofi Genzyme (teriflunomide)
  Teva (glatiramer acetate(confidentiality agreement not signed, not participating)
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee

Timeline

Key events during the development of the guidance:

Date Update
16 July 2019 Invitation to participate
16 July 2019 In progress, Appraisal has been referred to NICE.
20 November 2018 - 18 December 2018 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance